Also, the Company completed a five-for-one share split with  an effective date of 1 April 2014. However, the effect of such  share split is not reflected in “27. Share-based payment”. The Company accounts for those share-based payment  arrangements as equity-settled share-based payment  transactions. (2) Expenses recognised in the consolidated statements of income (3) Movement of the number of share options outstanding and their weighted average exercise price (4) Expiration dates and exercise prices of share options outstanding at the end of the period (Millions of yen) 2013 2014 Total expenses recognised for share options granted ¥374 ¥365 2013 2014 Weighted average  exercise price  (yen) Number of  shares Weighted average  exercise price  (yen) Number of  shares Outstanding, beginning of the period ¥ 464 645,900 ¥ 184 712,300 Granted 1 127,000 1 70,700 Exercised 2,782 (60,600) 1,199 (102,600) Forfeited or expired — — — — Outstanding, end of the period 184 712,300 12 680,400 Options exercisable, end of the period 193 680,550 13 662,725 Expiration  date Exercise price per share (yen) Number of shares 2013 2014 Granted on July 2003 (Note 1) 27 June 2013 ¥3,209 4,500 — Granted on July 2004 (Note 1) 24 June 2014 3,690 31,500 2,100 Granted on August 2005 (Note 2) 24 June 2025 1 41,300 28,400 Granted on February 2007 (Note 2) 27 June 2026 1 42,600 35,900 Granted on August 2007 (Note 2) 26 June 2027 1 57,300 50,300 Granted on September 2008 (Note 2) 24 June 2028 1 59,600 50,300 Granted on July 2009 (Note 2) 23 June 2029 1 99,500 87,100 Granted on July 2010 (Note 2) 23 June 2030 1 123,900 113,100 Granted on July 2011 (Note 2) 20 June 2031 1 125,100 115,500 Granted on July 2012 (Note 2) 20 June 2032 1 127,000 127,000 Granted on July 2013 (Note 2) 19 June 2033 1 — 70,700 Total — 712,300 680,400 (Note) 1. The number of share options is presented as the number of underlying shares. 2. The weighted average share price of share options at the time of exercise during the period is 4,380 yen for the year ended 31 March 2013 and 5,536 yen for the  year ended 31 March 2014. (Note) 1. There are no vesting conditions. 2. There are vesting conditions in which share subscription rights are vested according to the service record over approximately one year from the grant date of the  share option to the vesting date. 132 Astellas Pharma Inc.  _ Annual Report 2014